Video

How do we get the next 10 years right? w/ Joanna Shields, CogX

For the opening keynote of CogX 2020, our CEO Joanna Shields shared inspiration for the next decade, and answered the question “how do we get the next 10 years right”?

We had entered 2020 with such high hopes and dreams for the innovations that awaited us in the coming decade. Yet we were barely out of the gates when our world of infinite possibilities was brought to its knees by a deadly virus. The challenges that followed have been unprecedented in our lifetimes. 

As the disease raged through our communities and lockdowns were enforced, we all watched the daily news recount the number of souls who had lost their lives to COVID-19.  The profound economic shock continues to reverberate, and expose deep inequities in our society and in how we care for our citizens.

Our journey into this strange new normal also made us painfully aware of our own vulnerabilities and the fragility of human life. Above all, we have been reminded that our most valuable currency is not measured in wealth or possessions, but rather through our health.  

So, why can’t we build a world where no disease goes untreated? Why, with all of the advances in technology, are so many people still suffering from disease? The economic and development models urgently need to change. Patients deserve better. We must leverage breakthrough technologies for the benefit of all.

Above all, getting the next 10 years right demands leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all.

Watch the full speech here:


More Posts

You Might Also Like

News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
News
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022